Vol.67 No.4 July 2019
Susceptibility of antibiotic-resistant probiotics to anti-MRSA agents: Enterococcus faecalis in antibiotic-resistant probiotics is susceptible to linezolid
1)Department of Pharmacy, Kyushu Central Hospital, 3-23-1 Shiobaru, Minami-ku, Fukuoka, Fukuoka, Japan
2)Department of Clinical Laboratory, Kyushu Central Hospital
3)Department of Pharmacy, Fukuoka Tokushukai Hospital
Abstract
Diarrhea that occurs as an adverse effect to antibiotic treatment is known as antibiotic-associated diarrhea (AAD) and can be treated with antibiotic-resistant probiotics. Four species (six strains) of lactic acid bacteria are currently used in antibiotic-resistant probiotics, but whether they exhibit resistance to the antibiotics used to treat methicillin-resistant Staphylococcus aureus (MRSA) is unknown.
We therefore conducted in vitro tests of the susceptibility of six strains of lactic acid bacteria contained in antibiotic-resistant probiotics (Enterococcus faecalis 129 BIO 3B-R, E. faecalis BIO-4R, E. faecalis PCR, Lactobacillus acidophilus 4AR, Bifidobacterium infantis SMR, and Bifidobacterium longum LBR) to nine types of antibiotic used to treat MRSA: vancomycin (VCM), teicoplanin (TEIC), arbekacin, linezolid (LZD), daptomycin (DAP), sulfamethoxazole-trimethoprim, rifampicin (RFP), clindamycin (CLDM), and minocycline (MINO).
The minimum inhibitory concentrations (MICs) of VCM, TEIC, DAP, and MINO were all ≤1 μg/mL, and no obvious resistance to these antibiotics was observed. However, two strains (E. faecalis 129 BIO 3B-R and E. faecalis BIO-4R) exhibited resistance to LZD, three strains of Enterococcus exhibited resistance to RFP, and two strains (L. acidophilus 4AR and B. longum LBR) exhibited resistance to CLDM.
The first priority in the treatment of AAD is the withdrawal of the antibiotic causing the condition; however, if its use must be continued, the correct choice of the antibiotic-resistant probiotic that exhibits resistance to the specific antibiotic may lead to more effective improvements in gut flora.
Key word
probiotics, linezolid-resistance, enterococci, anti-MRSA agent, antibiotic-associated diarrhea
Received
October 15, 2018
Accepted
January 8, 2019
Jpn. J. Chemother. 67 (4): 483-487, 2019
